when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVARTIS · news · pharmadog

← back to NOVARTIS

News mentioning NOVARTIS

86 stories

16dJ&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsbiopharma dive

17dCelcuity wins approval for breast cancer drug Revtorpykendpoints

18dSTAT+: Pharmalittle: We’re reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and morestat

21dSTAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and morestat

22dSTAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and morestat

23dNovartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugsendpoints

23dSTAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and morestat

24dNovartis, Vertex and Ipsen extend pharma M&A spree from 2026's first halfendpoints

24dVertex to acquire Crinetics in $10B foray into endocrine disease drugsbiopharma dive

24dSTAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and morestat

25dSTAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversightstat

25dNovartis to acquire ADC developer in a deal worth up to $1.5Bbiopharma dive

25dSTAT+: Four major biotech updates to catch up onstat

25dSTAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and morestat

26dNovartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platformendpoints

29dSandoz launches direct-to-consumer platform with growth disorder drugendpoints

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 17, 26A new Westlake-backed biotech takes aim at migrainesbiopharma dive

Jun 15, 26STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to endstat

Jun 15, 26Covid vaccination cut risk of adverse heart events, large study findsstat

Jun 15, 26STAT+: Lilly’s Ajax acquisition may have been worth itstat

Jun 12, 26STAT+: Prometheus raises $12 billion in capital for artificial engineersstat

Jun 12, 26STAT+: At hospital finance conference, a call to end the friction that’s keeping costs highstat

Jun 11, 26STAT+: An obesity drug deep-dive, and peptides move mainstreamstat

Jun 11, 26Nonprofit buys experimental cancer drug to maintain patient accessstat

Jun 11, 26Study highlights influence of socioeconomic status on children’s brain developmentstat

Jun 11, 26STAT+: Abridge inks deals with Nvidia and Lillystat

Jun 11, 26STAT+: A suspicious denial pattern in Medicare Advantagestat

Jun 11, 26Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyendpoints

← prevpage 2 of 3next →